Glucagon regulates orexin a secretion in humans and rodents

Diabetologia

Volumn 57, Issue 10, 2014, Pages 2108-2116

  Arafat, Ayman M ^a,b   Kaczmarek, PrzemysŁAw ^c   Skrzypski, Marek ^a,c   PruszyŃSka OszmaŁEk, Ewa ^c   KoŁOdziejski, PaweŁ ^c   Adamidou, Aikaterini ^a   Ruhla, Stephan ^a   Szczepankiewicz, Dawid ^c   Sassek, Maciej ^a,c   Billert, Maria ^c   Wiedenmann, Bertram ^a   Pfeiffer, Andreas F H ^a,b   Nowak, Krzysztof W ^c   Strowski, Mathias Z ^a,d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^c POZNA UNIVERSITY OF LIFE SCIENCES   (Poland)

^d Elblandclinic   (Germany)

Author keywords

Adipocytes; Animal study; Endocrine pancreas; Glucose homeostasis; Hepatocytes; Human study; Secretion; Type 1 diabetes mellitus

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN; DIAZOXIDE; GLUCOSE; HUMAN INSULIN; INSULIN; INSULIN ANTIBODY; MESSENGER RNA; METFORMIN; OREXIN A; PLACEBO; RECOMBINANT GLUCAGON; GLUCAGON; NEUROPEPTIDE; OREXINS; SIGNAL PEPTIDE;

ADOLESCENT; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ENERGY EXPENDITURE; FEMALE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERINSULINEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN HYPOGLYCEMIA; INSULIN RELEASE; INSULIN TOLERANCE TEST; MALE; MIDDLE AGED; MOUSE; NON HUMAN INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET; PRIORITY JOURNAL; PROSPECTIVE STUDY; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ADIPOCYTE; ANIMAL; BAGG ALBINO MOUSE; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; METABOLISM; NORMAL HUMAN; PANCREAS; RANDOMIZED CONTROLLED TRIAL; SECRETION (PROCESS);

ADIPOCYTES; ADULT; ANIMALS; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; FEMALE; GLUCAGON; GLUCOSE; HEALTHY VOLUNTEERS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, INBRED BALB C; NEUROPEPTIDES; PANCREAS;

EID: 84926624951     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3335-4     Document Type: Article

References (44)

1. Sakurai T, Amemiya A, Ishii M et al (1998) Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92:573–585
2. Hara J, Beuckmann CT, Nambu T et al (2001) Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 30:345–354
3. Hara J, Yanagisawa M, Sakurai T (2005) Difference in obesity phenotype between orexin-knockout mice and orexin neuron-deficient mice with same genetic background and environmental conditions. Neurosci Lett 380:239–242
4. Funato H, Tsai AL, Willie JT et al (2009) Enhanced orexin receptor-2 signaling prevents diet-induced obesity and improves leptin sensitivity. Cell Metab 9:64–76
5. Sellayah D, Bharaj P, Sikder D (2011) Orexin is required for brown adipose tissue development, differentiation, and function. Cell Metab 14:478–490
6. de Lecea L, Kilduff TS, Peyron C et al (1998) The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 95:322–327
7. Marcus JN, Aschkenasi CJ, Lee CE et al (2001) Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol 435: 6–25
8. Nakabayashi M, Suzuki T, Takahashi K et al (2003) Orexin-A expression in human peripheral tissues. Mol Cell Endocrinol 205: 43–50
9. Blanco M, Lopez M, Garcia-Caballero T et al (2001) Cellular localization of orexin receptors in human pituitary. J Clin Endocrinol Metab 86:1616–1619
10. Johren O, Bruggemann N, Dendorfer A, Dominiak P (2003) Gonadal steroids differentially regulate the messenger ribonucleic acid expression of pituitary orexin type 1 receptors and adrenal orexin type 2 receptors. Endocrinology 144:1219–1225
11. Rodgers RJ, Halford JC, Nunes de Souza RL et al (2001) SB-334867, a selective orexin-1 receptor antagonist, enhances behavioural satiety and blocks the hyperphagic effect of orexin-A in rats. Eur J Neurosci 13:1444–1452
12. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E (2000) Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355:39–40
13. Nishino S, Ripley B, Overeem S et al (2001) Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 50:381–388
14. Peyron C, Faraco J, Rogers W et al (2000) A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 6:991–997
15. Siegel JM, Moore R, Thannickal T, Nienhuis R (2001) A brief history of hypocretin/orexin and narcolepsy. Neuropsychopharmacology 25: S14–S20
16. Honda Y, Doi Y, Ninomiya R, Ninomiya C (1986) Increased frequency of non-insulin-dependent diabetes mellitus among narcolep-tic patients. Sleep 9:254–259
17. Sakurai T (2005) Roles of orexin/hypocretin in regulation of sleep/ wakefulness and energy homeostasis. Sleep Med Rev 9:231–241
18. Tsuneki H, Murata S, Anzawa Y et al (2008) Age-related insulin resistance in hypothalamus and peripheral tissues of orexin knockout mice. Diabetologia 51:657–667
19. Tsuneki H, Sugihara Y, Honda R, Wada T, Sasaoka T, Kimura I (2002) Reduction of blood glucose level by orexins in fasting normal and streptozotocin-diabetic mice. Eur J Pharmacol 448:245–252
20. Harada S, Yamazaki Y, Tokuyama S (2013) Orexin-A suppresses postischemic glucose intolerance and neuronal damage through hy-pothalamic brain-derived neurotrophic factor. J Pharmacol Exp Ther 344:276–285
21. Shiuchi T, Haque MS, Okamoto S et al (2009) Hypothalamic orexin stimulates feeding-associated glucose utilization in skeletal muscle via sympathetic nervous system. Cell Metab 10:466–480
22. Ducroc R, Voisin T, El Firar A, Laburthe M (2007) Orexins control intestinal glucose transport by distinct neuronal, endocrine, and direct epithelial pathways. Diabetes 56:2494–2500
23. Skrzypski M, Le TT, Kaczmarek P et al (2011) Orexin A stimulates glucose uptake, lipid accumulation and adiponectin secretion from 3T3-L1 adipocytes and isolated primary rat adipocytes. Diabetologia 54:1841–1852
24. Switonska MM, Kaczmarek P, Malendowicz LK, Nowak KW (2002) Orexins and adipoinsular axis function in the rat. Regul Pept 104:69–73
25. Nowak KW, Strowski MZ, Switonska MM et al (2005) Evidence that orexins A and B stimulate insulin secretion from rat pancreatic islets via both receptor subtypes. Int J Mol Med 15:969–972
26. Goncz E, Strowski MZ, Grotzinger C et al (2008) Orexin-A inhibits glucagon secretion and gene expression through a Fox01-dependent pathway. Endocrinology 149:1618–1626
27. Ehrstrom M, Naslund E, Levin F et al (2004) Pharmacokinetic profile of orexin A and effects on plasma insulin and glucagon in the rat. Regul Pept 119:209–212
28. Ouedraogo R, Naslund E, Kirchgessner AL (2003) Glucose regulates the release of orexin-a from the endocrine pancreas. Diabetes 52:111– 117
29. Consoli A (1992) Role of liver in pathophysiology of NIDDM. Diabetes Care 15:430–441
30. Komaki G, Matsumoto Y, Nishikata H et al (2001) Orexin-A and leptin change inversely in fasting non-obese subjects. Eur J Endocrinol 144:645–651
31. Arafat AM, Kaczmarek P, Skrzypski M et al (2013) Glucagon increases circulating fibroblast growth factor 21 independently of endogenous insulin levels: a novel mechanism of glucagon-stimulated lipolysis? Diabetologia 56:588–597
32. Arafat MA, Otto B, Rochlitz H et al (2005) Glucagon inhibits ghrelin secretion in humans. Eur J Endocrinol 153:397–402
33. Arafat AM, Perschel FH, Otto B et al (2006) Glucagon suppression of ghrelin secretion is exerted at hypothalamus-pituitary level. J Clin Endocrinol Metab 91:3528–3533
34. Lee Y, Wang MY, Du XQ, Charron MJ, Unger RH (2011) Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes 60:391–397
35. Skrzypski M, Kakkassery M, Mergler S et al (2013) Activation of TRPV4 channel in pancreatic INS-1E beta cells enhances glucose-stimulated insulin secretion via calcium-dependent mechanisms. FEBS Lett 587:3281–3287
36. Dostmann WR (1995) (RP) cAMPS inhibits the cAMP dependent protein kinase by blocking the cAMP induced conformational transition. FEBS Lett 375:231–234
37. Goode PN, Farndon JR, Anderson J, Johnston ID, Morte JA (1986) Diazoxide in the management of patients with insulinoma. World J Surg 10:586–592
38. Trube G, Rorsman P (1986) Calcium and potassium currents recorded from pancreatic beta-cells under voltage clamp control. Adv Exp Med Biol 211:167–175
39. Gilon P, Henquin JC (1992) Influence of membrane potential changes on cytoplasmic Ca2+ concentration in an electrically excitable cell, the insulin-secreting pancreatic B cell. J Biol Chem 267:20713–20720
40. Urdanivia E, Pek S, Santiago JC (1979) Inhibition of glucagon secretion by diazoxide in vitro. Diabetes 28:26–31
41. Cherrington AD (1997) The metabolic actions of glucagon. In: Draznin B, Rizza E (eds) Clinical research in diabetes and obesity, volume 1: methods, assessment, and metabolic regulation (contemporary biomedicine), 1st edn. Humana Press, Totowa, p 222
42. Geary N, Kissileff HR, Pi Sunyer FX, Hinton V (1992) Individual, but not simultaneous, glucagon and cholecystokinin infusions inhibit feeding in men. Am J Physiol 262:R975–R980
43. Geary N (1990) Pancreatic glucagon signals postprandial satiety. Neurosci Biobehav Rev 14:323–338
44. Vanderweele DA, Macrum BL, Oetting RL (1986) Glucagon, satiety from feeding and liver/pancreatic interactions. Brain Res Bull 17: 539–543